Chimeric Vaccines against Hyper Evolving Pathogens
This special issue belongs to the section "Vaccines Against Tropical and Other Infectious Diseases".
Special Issue Information
Chimeric vaccines can be an effective strategy to combat infectious diseases. The conventional examples include the RTS/S vaccine, which the World Health Organization has recommended for pilot implementation against malaria. The chimeric vaccine approach has also been employed in the FDA-approved vaccine BEXSERO against Neisseria meningitidis serogroup B. BEXSERO includes the chimeric fused antigen of Neisserial Heparin Binding Antigen from strain NZ98/254 and accessory protein 953 from strain 2996. The fusion protein of factor H binding protein from strain MC58 and accessory protein 936 from strain 2996 is also included in BEXSERO. The chimeric vaccine enabled the efficient representation of antigenic repertories and resolved a “deadlock” on vaccine development for malaria and Neisseria meningitidis serogroup B.
This Special Issue invites high-quality research in the development of chimeric vaccine and epitope variations in the newer strains/serotypes of various pathogens. This will include immune determinant polymorphisms’ epidemiology, computational design/screening, mice studies, rational vaccine design and development, immune cell type response and field studies.
Dr. Yash Gupta
Dr. Manish Manish
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multi-epitopic vaccine
- vaccine design
- reverse vaccinology
- potential vaccine candidate
- epitope-scaffolding
- epitope-mapping
- epitope grafting
- multi-graft scaffolding
- immunoinformatics approach
- immunization
- rational design
- structural vaccinology
- immunogen design
- immuno focusing
- protein engineering
- antiviral immunotherapy
- antibody engineering
- antibodyomics tools
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Published Papers
Vaccines - ISSN 2076-393X